Compare RLJ & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLJ | NVAX |
|---|---|---|
| Founded | 2011 | 1987 |
| Country | United States | United States |
| Employees | 73 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 1996 |
| Metric | RLJ | NVAX |
|---|---|---|
| Price | $8.85 | $9.23 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 9 |
| Target Price | $7.83 | ★ $11.33 |
| AVG Volume (30 Days) | 3.0M | ★ 4.5M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.26% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $2.02 | N/A |
| Revenue Next Year | $2.54 | N/A |
| P/E Ratio | $188.67 | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $6.54 | $6.20 |
| 52 Week High | $9.00 | $11.85 |
| Indicator | RLJ | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 70.49 | 55.25 |
| Support Level | $7.24 | $9.14 |
| Resistance Level | N/A | $10.63 |
| Average True Range (ATR) | 0.24 | 0.61 |
| MACD | 0.05 | 0.18 |
| Stochastic Oscillator | 88.26 | 49.01 |
RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.